These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 17325237

  • 1. Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure.
    Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Lapp H, Stasch JP, Burnett JC.
    Hypertension; 2007 May; 49(5):1128-33. PubMed ID: 17325237
    [Abstract] [Full Text] [Related]

  • 2. Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure.
    Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Tsuruda T, Harty GJ, Lapp H, Stasch JP, Burnett JC.
    Circulation; 2003 Feb 11; 107(5):686-9. PubMed ID: 12578869
    [Abstract] [Full Text] [Related]

  • 3. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
    Boerrigter G, Burnett JC.
    Cardiovasc Drug Rev; 2007 Feb 11; 25(1):30-45. PubMed ID: 17445086
    [Abstract] [Full Text] [Related]

  • 4. Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptide in dogs with severe congestive heart failure using a specific antagonist for guanylate cyclase-coupled receptors.
    Wada A, Tsutamoto T, Matsuda Y, Kinoshita M.
    Circulation; 1994 May 11; 89(5):2232-40. PubMed ID: 7910118
    [Abstract] [Full Text] [Related]

  • 5. Targeting heme-oxidized soluble guanylate cyclase: solution for all cardiorenal problems in heart failure?
    Münzel T, Genth-Zotz S, Hink U.
    Hypertension; 2007 May 11; 49(5):974-6. PubMed ID: 17325236
    [No Abstract] [Full Text] [Related]

  • 6. M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics.
    McKie PM, Cataliotti A, Ichiki T, Sangaralingham SJ, Chen HH, Burnett JC.
    J Am Heart Assoc; 2014 Jan 02; 3(1):e000206. PubMed ID: 24385449
    [Abstract] [Full Text] [Related]

  • 7. Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure.
    Lapp H, Mitrovic V, Franz N, Heuer H, Buerke M, Wolfertz J, Mueck W, Unger S, Wensing G, Frey R.
    Circulation; 2009 Jun 02; 119(21):2781-8. PubMed ID: 19451356
    [Abstract] [Full Text] [Related]

  • 8. Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation.
    Evgenov OV, Kohane DS, Bloch KD, Stasch JP, Volpato GP, Bellas E, Evgenov NV, Buys ES, Gnoth MJ, Graveline AR, Liu R, Hess DR, Langer R, Zapol WM.
    Am J Respir Crit Care Med; 2007 Dec 01; 176(11):1138-45. PubMed ID: 17872487
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cinaciguat, a soluble guanylate cyclase activator for the potential treatment of acute heart failure.
    Tamargo J, Duarte J, Caballero R, Delpón E.
    Curr Opin Investig Drugs; 2010 Sep 01; 11(9):1039-47. PubMed ID: 20730699
    [Abstract] [Full Text] [Related]

  • 11. Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation.
    Meurer S, Pioch S, Pabst T, Opitz N, Schmidt PM, Beckhaus T, Wagner K, Matt S, Gegenbauer K, Geschka S, Karas M, Stasch JP, Schmidt HH, Müller-Esterl W.
    Circ Res; 2009 Jul 02; 105(1):33-41. PubMed ID: 19478201
    [Abstract] [Full Text] [Related]

  • 12. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels.
    Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, H S AK, Meurer S, Deile M, Taye A, Knorr A, Lapp H, Müller H, Turgay Y, Rothkegel C, Tersteegen A, Kemp-Harper B, Müller-Esterl W, Schmidt HH.
    J Clin Invest; 2006 Sep 02; 116(9):2552-61. PubMed ID: 16955146
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The effects of cyclic guanylate cyclase stimulation on right ventricular hypertrophy and failure alone and in combination with phosphodiesterase-5 inhibition.
    Andersen A, Nielsen JM, Holmboe S, Vildbrad MD, Nielsen-Kudsk JE.
    J Cardiovasc Pharmacol; 2013 Aug 02; 62(2):167-73. PubMed ID: 23575263
    [Abstract] [Full Text] [Related]

  • 17. Preconditioning with soluble guanylate cyclase activation prevents postischemic inflammation and reduces nitrate tolerance in heme oxygenase-1 knockout mice.
    Wang WZ, Jones AW, Wang M, Durante W, Korthuis RJ.
    Am J Physiol Heart Circ Physiol; 2013 Aug 15; 305(4):H521-32. PubMed ID: 23771693
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.